223 related articles for article (PubMed ID: 17430207)
1. True antisense oligonucleotides with modified nucleotides restricted in the N-conformation.
Koizumi M
Curr Top Med Chem; 2007; 7(7):661-5. PubMed ID: 17430207
[TBL] [Abstract][Full Text] [Related]
2. An overview of sugar-modified oligonucleotides for antisense therapeutics.
Prakash TP
Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo.
Shen L; Siwkowski A; Wancewicz EV; Lesnik E; Butler M; Witchell D; Vasquez G; Ross B; Acevedo O; Inamati G; Sasmor H; Manoharan M; Monia BP
Antisense Nucleic Acid Drug Dev; 2003; 13(3):129-42. PubMed ID: 12954113
[TBL] [Abstract][Full Text] [Related]
4. Structural insight into antisense gapmer-RNA oligomer duplexes through molecular dynamics simulations.
Uppuladinne MVN; Sonavane UB; Deka RC; Joshi RR
J Biomol Struct Dyn; 2019 Jul; 37(11):2823-2836. PubMed ID: 30284504
[TBL] [Abstract][Full Text] [Related]
5. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA.
Vester B; Wengel J
Biochemistry; 2004 Oct; 43(42):13233-41. PubMed ID: 15491130
[TBL] [Abstract][Full Text] [Related]
6. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide.
Fluiter K; Frieden M; Vreijling J; Rosenbohm C; De Wissel MB; Christensen SM; Koch T; Ørum H; Baas F
Chembiochem; 2005 Jun; 6(6):1104-9. PubMed ID: 15861430
[TBL] [Abstract][Full Text] [Related]
7. Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2'-deoxy-2'-fluoro-D-arabinose and 2'-deoxyribose nucleotides.
Lok CN; Viazovkina E; Min KL; Nagy E; Wilds CJ; Damha MJ; Parniak MA
Biochemistry; 2002 Mar; 41(10):3457-67. PubMed ID: 11876654
[TBL] [Abstract][Full Text] [Related]
8. 2'-O,4'-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug.
Morita K; Hasegawa C; Kaneko M; Tsutsumi S; Sone J; Ishikawa T; Imanishi T; Koizumi M
Bioorg Med Chem Lett; 2002 Jan; 12(1):73-6. PubMed ID: 11738576
[TBL] [Abstract][Full Text] [Related]
9. Triazole- and Tetrazole-Bridged Nucleic Acids: Synthesis, Duplex Stability, Nuclease Resistance, and in Vitro and in Vivo Antisense Potency.
Mitsuoka Y; Yamamoto T; Kugimiya A; Waki R; Wada F; Tahara S; Sawamura M; Noda M; Fujimura Y; Kato Y; Hari Y; Obika S
J Org Chem; 2017 Jan; 82(1):12-24. PubMed ID: 27936689
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and properties of 2',4'-BNA(NC): a bridged nucleic acid analogue.
Rahman SM; Seki S; Obika S; Yoshikawa H; Miyashita K; Imanishi T
J Am Chem Soc; 2008 Apr; 130(14):4886-96. PubMed ID: 18341342
[TBL] [Abstract][Full Text] [Related]
11. Double sugar and phosphate backbone-constrained nucleotides: synthesis, structure, stability, and their incorporation into oligodeoxynucleotides.
Zhou C; Plashkevych O; Chattopadhyaya J
J Org Chem; 2009 May; 74(9):3248-65. PubMed ID: 19348480
[TBL] [Abstract][Full Text] [Related]
12. 2'-Modified oligonucleotides for antisense therapeutics.
Prakash TP; Bhat B
Curr Top Med Chem; 2007; 7(7):641-9. PubMed ID: 17430205
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of ENA Nucleotides and ENA Oligonucleotides.
Morita K; Koizumi M
Curr Protoc Nucleic Acid Chem; 2018 Mar; 72(1):4.79.1-4.79.21. PubMed ID: 29927121
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of VEGF mRNA expression by 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) antisense oligonucleotides and investigation of non-target gene expression.
Morita K; Yamate K; Kurakata S; Abe K; Imanishi T; Koizumi M
Nucleic Acids Res Suppl; 2002; (2):99-100. PubMed ID: 12903124
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and properties of 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) as effective antisense oligonucleotides.
Morita K; Takagi M; Hasegawa C; Kaneko M; Tsutsumi S; Sone J; Ishikawa T; Imanishi T; Koizumi M
Bioorg Med Chem; 2003 May; 11(10):2211-26. PubMed ID: 12713831
[TBL] [Abstract][Full Text] [Related]
16. 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) with nuclease-resistance and high affinity for RNA.
Morita K; Hasegawa C; Kaneko M; Tsutsumi S; Sone J; Ishikawa T; Imanishi T; Koizumi M
Nucleic Acids Res Suppl; 2001; (1):241-2. PubMed ID: 12836354
[TBL] [Abstract][Full Text] [Related]
17. ENA oligonucleotides as therapeutics.
Koizumi M
Curr Opin Mol Ther; 2006 Apr; 8(2):144-9. PubMed ID: 16610767
[TBL] [Abstract][Full Text] [Related]
18. 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) as next-generation antisense and antigene agents.
Koizumi M
Biol Pharm Bull; 2004 Apr; 27(4):453-6. PubMed ID: 15056846
[TBL] [Abstract][Full Text] [Related]
19. In vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA in comparison of that of 2'-MOE-modified oligonucleotides.
Koizumi M; Takagi-Sato M; Okuyama R; Araki K; Sun W; Nakai D
Nucleic Acids Symp Ser (Oxf); 2007; (51):111-2. PubMed ID: 18029611
[TBL] [Abstract][Full Text] [Related]
20. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
